VIP International Capital Appreciation Portfolio OCSE:NOVO B Holdings History

Number of Shares

N/A

% of Portfolio

Total Estimate Gain

kr72.56 Mil

% of Total Estimate Gain

49.93%

VIP International Capital Appreciation Portfolio's Novo Nordisk AS Holding Summary

As of 2025-03-31, VIP International Capital Appreciation Portfolio held - shares of Novo Nordisk AS(OCSE:NOVO B), totaling N/A. This investment constitutes 0% of their stock portfolio, and VIP International Capital Appreciation Portfolio now holds 0% of the outstanding Novo Nordisk AS(OCSE:NOVO B) stock.

The initial trade took place in 2019Q4. And since then VIP International Capital Appreciation Portfolio has made 7 purchases of OCSE:NOVO B, at an average price of kr267.35, for a total of 543,553.00 shares. In addition, there have been 13 sales at an average price of kr400.84 for 543,553.00 shares. Based on historical transaction data and OCSE:NOVO B's current price of kr447.05, VIP International Capital Appreciation Portfolio's estimated gain on his OCSE:NOVO B holdings is kr72.56 Mil, reflecting a 49.93% gain to date.

VIP International Capital Appreciation Portfolio OCSE:NOVO B (kr447.05) Holding Chart

VIP International Capital Appreciation Portfolio OCSE:NOVO B (kr447.05) Quarterly Buys and Sells

Period	Bought/Sold (Sh.)	% Change
Shares Bought	0	Average Price kr-/Share
Shares Sold	0	Average Price kr-/Share
Current Price kr0.00		Total Estimated Gain 0 %

Top Ranked Articles

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.